US 12,746,598 B2 · Bimetallic fluorescent nanocomposites for cancer theranostics

Abstract

Fluorescent bimetallic nanocomposites (M1@M2-NCs) of silver-gold (Ag@Au-NC) and silver-platinum (Ag@Pt-NC) are prepared by reducing silver nitrate (AgNO3) on gold nanoparticles (AuNPs) and platinum nanoparticles (PtNPs) using sodium borohydride (NaBH4) at alkaline pH=11, in the presence of a lysozyme that acts as a template, and in the presence of a capping and stabilizing agent. The biocompatible bimetallic nanocomposites (M1@M2-NCs) have promising multifunctional applications (cell imaging, bio-sensing, therapeutics) observed by both in vitro as well as in vivo experiments. The fluorescent bimetallic nanocomposites (M1@M2-NCs) of silver-gold (Ag@Au-NC) and silver-platinum (Ag@Pt-NC) may be useful as an alternative nanomedicine in cancer theranostics applications.

Claims15

Dependent claims

A bimetallic fluorescent nanocomposite comprising:

(i) a metal M1 as an outer layer of the nanocomposite;
(ii) a metal M2 as an inner metallic layer of the nanocomposite;
and
(iii) a capping agent,
wherein:
the metal M1 is selected from the group consisting of silver, chromium, manganese, iron, cobalt, nickel, copper, zinc, magnesium, and calcium;
the metal M2 is a metal nanoparticle selected from the group consisting of gold, platinum, chromium, magnesium, calcium, copper, palladium, manganese, cobalt, nickel, titanium, zinc, cerium, iron, and thallium;
the capping agent is a lysozyme protein;
and
the lysozyme protein is a biocompatible globular protein.

7 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/909,239Filed 5 Mar 2021

Priority

IN 2020110096706 Mar 2020

Published

US 2023/0086363 A123 Mar 2023

Granted

29 Sep 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification16 codes

B22F 9/24
With reduction of metal compounds: starting from liquid metal compounds, e.g. solutions
A61K 47/64
The modifying agent being a protein, peptide or polyamino acid: drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying…
A61K 49/0019
Fluorescence in vivo: characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
A61K 49/0056
Characterised by the carrier molecule carrying the fluorescent agent: peptides, proteins, polyamino acids

Bimetallic fluorescent nanocomposites for cancer theranostics

Life of this patent

Bimetallic fluorescent nanocomposites for cancer theranostics

Life of this patent

Abstract

Claims15